Insider Buying: Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $3,351,032.83 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock in a transaction on Friday, June 12th. The stock was acquired at an average price of $8.57 per share, for a total transaction of $3,351,032.83. Following the purchase, the director owned 16,622,736 shares of the company’s stock, valued at approximately $142,456,847.52. This trade represents a 2.41% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.99 per share, for a total transaction of $138,571.86.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $9.82 on Friday. The company has a market capitalization of $242.75 million, a PE ratio of -2.77 and a beta of 2.38. The company has a 50 day moving average price of $9.13 and a 200-day moving average price of $6.32. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at $41,000. Bank of America Corp DE lifted its stake in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth $53,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics during the second quarter valued at about $58,000. Finally, Jane Street Group LLC bought a new stake in Artiva Biotherapeutics during the second quarter valued at about $67,000.

Analysts Set New Price Targets

Several brokerages have recently commented on ARTV. Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.